Mid-Term Outcomes of Primary Hip Replacement in Patients with End-Stage Chronic Renal Disease

封面


如何引用文章

详细

Purpose — to evaluate mid-term outcomes of primary hip replacement in patients with end-stage chronic renal disease and to develop an algorithm for selection of surgical tactics and perioperative treatment.

Materials and Methods. The authors evaluated outcomes of primary hip replacement in 45 patients receiving renal substitution therapy and 47 patients without chronic renal disease. Patients with end-stage chronic renal disease (CRD) were divided into two groups: group I included 30 (66.6%) patients receiving chronic hemodialysis (CH) and group II included 15 (33.4%) patients after renal transplantation (RT). Group III of 47 (51.1%) patients without any signs of CRD who underwent hip arthroplasty within relevant period of time was established to evaluate the effectiveness of primary hip replacement. Blood serum Ca2+ and P5+ levels as well as levels of parathyroid hormone (PTH) and 1.25-dihydroxyvitamin D were measured to determine the rate of calcium- phosphoric metabolism disturbance. Multi-spiral CT scans of hip joint were performed to identify bone mineral density and the mean Hounsfield (Hu) value was calculated for which the data was obtained from five various points on the proximal femur and acetabulum. Beta-2 microglobulin (B2M) blood test was performed to confirm amyloid bone disease.

Results. The authors did not observe statistically significant differences for arthroplasty outcomes in patients of group II and III. Patients receiving long-term hemodialysis demonstrated significantly lower parameters of Harris score and Barthel’s index of social adaptation after hip replacement as compared to groups II and III: patients of group I demonstrated outcomes improvement at 19.55%, in group II — at 13.03%, in group III — at 10.15% as compared to preoperative status. Decrease of 1.25-dihydroxyvitamin D below 20,0 mcg results in resorption of cancellous bone in proximal femur and acetabulum along with myopathy of gluteus muscles. Sharp increase of parathyroid hormone level (over 600 pcg/ml) was accompanied by inhibition of osteoblasts proliferation and differentiation resulting in substantial impairment of mineralization.

Conclusion. According to the algorithm suggested by the authors the key parameters that need to be evaluated in preoperative period are parathyroid hormone (PTH) and 1.25-dihydroxyvitamin D. Five-fold increase of PTH (>600 pcg/ml) demands parathyroidectomy as the first stage of treatment to decrease risk of early aseptic loosening of hip prosthesis and development of periprosthetic fracture.

作者简介

A. Tsed

Pavlov First Saint Petersburg State Medical University

编辑信件的主要联系方式.
Email: tsed@mail.ru

Alexander N. Tsed — Cand. Sci. (Med.), assistant professor, the head of Department of Traumatology and Orthopedics, Research Institute of Surgery and Emergency Medicine

St. Petersburg 俄罗斯联邦

A. Dulaev

Pavlov First Saint Petersburg State Medical University

Email: fake@neicon.ru

Alexander K. Dulaev — Dr. Sci. (Med.), professor, the head of Department of Traumatology and Orthopedics, Research Institute of Surgery and Emergency Medicine

St. Petersburg

俄罗斯联邦

N. Mushtin

Pavlov First Saint Petersburg State Medical University

Email: fake@neicon.ru

Nikita E. Mushtin — lecturer, Department of Traumatology and Orthopedics; orthopedic surgeon, Research Institute of Surgery and Emergency Medicine

St. Petersburg 俄罗斯联邦

K. Iliushchenko

Pavlov First Saint Petersburg State Medical University

Email: fake@neicon.ru

Konstantin G. Iliushchenko — orthopedic surgeon, Department of Traumatology and Orthopedics, Research Institute of Surgery and Emergency Medicine

St. Petersburg 俄罗斯联邦

A. Shmelev

Pavlov First Saint Petersburg State Medical University

Email: fake@neicon.ru

Anton V. Shmelev — orthopedic surgeon, Department of Traumatology and Orthopedics, Research Institute of Surgery and Emergency Medicine

St. Petersburg

俄罗斯联邦

参考

  1. Moe S., Drüeke T., Cunningham J., Goodman W., Martin K., Olgaard K. et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953. doi: 10.1038/sj.ki.5000414.
  2. Dember L.M., Jaber B.L. Dialysis-related amyloidosis: late finding or hidden epidemic? Semin Dial. 2006;19(2):105-109. doi: 10.1111/j.1525-139x.2006.00134.x.
  3. Jadoul M. Dialysis-related amyloidosis: importance of biocompatibility and age. Nephrol Dial Transplant. 1998;13 Suppl 7:61-64. doi: 10.1093/ndt/13.suppl_7.61.
  4. Bucci J.R., Oglesby R.J., Agodoa L.Y., Abbot K.C. Hospitalizations for total hip arthroplasty after renal transplantation in the united States. Am J Transplant. 2002;2:999-1004.
  5. Murphey M.D., Sartoris D.J., Quale J.L., Pathria M.N., Martin N.L. Musculoskeletal manifestations of chronic renal insufficiency. Radiographics. 1993;13(2):357-379. doi: 10.1148/radiographics.13.2.8460225.
  6. Fukunishi S., Yoh K., Yoshiya S. Bone graft for large bone cysts of the femoral neck in patients on hemodialysis. Clin Orthop Relat Res. 2007;461:175-179.
  7. Nagoya S., Nagao M., Takada J., Kuwabara H., Kaya M., Yamashita T. Efficacy of cementless total hip arthroplasty in patients on long-term hemodialysis. J Arthroplasty. 2005;20(1):66-71.
  8. Дулаев А.К., Цед А.Н., Фильченко И.А., Муштин Н.Е. Особенности влияния различных форм витамина D на костно-суставную систему. Ученые записки Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова. 2018;25(2): 19-31. doi: 10.24884/1607-4181-2018-25-2-19-31.
  9. Lieberman J.R., Fuchs M.D., Haas S.B., Garvin K.L., Goldstock L., Gupta R. et al. Hip arthroplasty in patients with chronic renal failure. J Arthroplasty. 1995;10(2):191-195.
  10. Ponnusamy K.E., Jain A., Thakkar S.C., Sterling R.S., Skolasky R.L., Khanuja H.S. Inpatient mortality and morbidity for dialysis-dependent patients undergoing primary total hip or knee arthroplasty. J Bone Joint Surg Am. 2015;97(16):1326-1332. doi: 10.2106/jBjS.N.01301.
  11. Cavanaugh P.K., Chen A.F., Rasouli M.R., Post Z.D., Orozco F.R., Ong A.C. Complications and mortality in chronic renal failure patients undergoing total joint arthroplasty: a comparison between dialysis and renal transplant patients. J Arthroplasty. 2016;31(2):465-472. doi: 10.1016/j.arth.2015.09.003.
  12. Цед А.Н., Дулаев А.К. Первичное эндопротезирование тазобедренного сустава у больных с терминальной стадией хронической болезни почек (обзор литературы). Травматология и ортопедия России. 2018;24(2):146-153. doi: 10.21823/2311-2905-2018-24-2-146-153.
  13. Molino D., De Lucia D., Gaspare De Santo N. Coagulation disorders in uremia. Semin Nephrol. 2006;26(1):46-51. doi: 10.1016/j.semnephrol.2005.06.011.
  14. Anderson R.J., O’Brien M., Mawhinney S., Villanueva C.B., Moritz T.E. et al. Renal failure predisposes patients to adverse outcome after coronary artery bypass surgery. VA cooperative Study #5. Kidney Int. 1999;55(3):1057-1062.
  15. Mathew A., Devereaux P.J., O’Hare A., Tonelli M., Thiessen-Philbrook H., Nevis I.F. et al. Chronic kidney disease and postoperative mortality: a systematic review and meta-analysis. Kidney Int. 2008;73(9):1069-1081. doi: 10.1038/KI.2008.29.
  16. Sakalkale D.P., Hozack W.J., Rothman R.H. Total hip arthroplasty in patients on long-term renal dialysis. J Arthroplasty. 1999;14(5):571-575.
  17. García-Ramiro S., Cofán F., Esteban P.L., Riba J., Gallart X., Oppenheimer F. et al. Total hip arthroplasty in hemodialysis and renal transplant patients. Hip Int. 2008;18(1):51-57.
  18. Lim B.H., Lim S.J., Moon Y.W., Park Y.S. Cementless total hip arthroplasty in renal transplant patients. Hip Int. 2012;22(5):516-520. doi: 10.5301/HIP.2012.9471.
  19. Wind T.C., Barfield W.R., Moskal J.T. The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty. J Arthroplasty. 2013;28(7):1080-1083. doi: 10.1016/j.arth.2012.11.016.
  20. Дулаев А.К., Цед А.Н., Муштин Н.Е. Применение транексамовой кислоты при эндопротезировании тазобедренного сустава у пациентов, находящихся на хроническом гемодиализе. Вестник хирургии им. И.И. Грекова. 2018;177(4):47-51. doi: 10.24884/0042-4625-2018-177-4-47-51.
  21. Maïz H.B., Abderrahim E., Zouaghi K. Anemia and endstage renal disease in the developing world. Artif Organs. 2002;26(9):760-764.
  22. Lasocki S., Krauspe R., von Heymann C. The prevalence of perioperative anaemia and need for patient blood management in elective orthopaedic surgery: a multicentre, observational study. Eur J Anaesthesiol. 2015;32(3):60-167. doi: 10.1097/eja.0000000000000202.
  23. Неверов В.А., Климов А.В., Раед С. Отдаленные результаты эндопротезирования тазобедренного сустава у больных с хронической почечной недостаточностью. Травматология и ортопедия России. 2006;(2):214-215.
  24. Rolighed L., Rejnmark L., Christiansen P. Bone involvement in primary hyperparathireoidism and changes afterparathreoidectomy. Eur Endocrinol. 2014;10(1):84-87. doi: 10.17925/ee.2014.10.01.84.
  25. Chan H.W., Chu K.H., Fung S.K., Tang H.L., Lee W., Cheuk A. et al. Prospective study on dialysis patients after total parathyroidectomy without autoimplant. Nephrology (Carlton). 2010;15(4):441-447. doi: 10.1111/j.1440-1797.2009.01257.x.

补充文件

附件文件
动作
1. JATS XML

版权所有 © ,



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 82474 от 10.12.2021.


##common.cookie##